Physician profile
Christa Marie Widjaja
NPI 1053920546
$3,659.77
in general payments reported to CMS, 2019-2025
17 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $227 · 2021: $800 · 2022: $670 · 2023: $941 · 2024: $611 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $755.79 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $530.89 | 2020-2025 | Acuvue, Axert |
| Glaukos Corporation | $368.56 | 2020-2024 | Ce-Marked Kxla System |
| Oyster Point Pharma, INC. | $262.98 | 2023 | Tyrvaya |
| Alcon Vision LLC | $247.04 | 2021-2025 | Total30, Precision 7, Precision7 |
| Kala Pharmaceuticals, INC. | $243.57 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $139.85 | 2021 | |
| Abbvie INC. | $138.92 | 2023 | Vuity, Lumigan |
| Dompe US, INC. | $137.10 | 2021-2024 | Oxervate |
| Novartis Pharmaceuticals Corporation | $136.08 | 2022-2023 | |
| Coopervision INC. | $132.39 | 2020-2025 | Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $130.06 | 2022-2024 | |
| Allergan, INC. | $121.87 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $113.42 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $97.37 | 2024-2025 | Vevye |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $81.84 | 2023-2025 | Xiidra, Miebo |
| Sight Sciences, INC. | $22.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christa Widjaja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.